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0735-6757/© 2016 The Authors. Published by Elsevier IncAs expected with all antithrombotic agents, there is a risk of bleeding complications in patients receiving direct
oral anticoagulants (DOACs) because of theDOAC itself, acute trauma, invasive procedures, or underlying comor-
bidities. For many bleeding events, a prudent course of action will be towithdraw the DOAC, then “wait and sup-
port” the patient, with the expectation that the bleeding event should resolvewith time. Likewise, DOAC therapy
may be interrupted ahead of a planned procedure, the stopping time being dependent on the agent involved and
the patient’s renal function. However, urgent reversal of anticoagulation is required in patients with serious or
life-threatening bleeding or in those requiring urgent surgery or procedures. Novel speciﬁc reversal agents, either
under development or recently approved, will need to be incorporated into local anticoagulation reversal proto-
cols. For dabigatran-treated patients, idarucizumab recently has been approved for clinical use in cases of life-
threatening or uncontrolled bleeding orwhen patients require emergency surgery or urgent procedures, both as-
sociated with a high risk of bleeding. As clinical experience with individual speciﬁc reversal agents grows, their
roles inmanaging major bleeding events in DOAC—treated patients will become better deﬁned. Future research,
as well as ongoing use of idarucizumab, should help establish when it is appropriate to re-dose with
idarucizumab, coadminister with prothrombin complex concentrates, or re-initiate DOAC after idarucizumab
use. Ongoing trials should help identify the appropriate doses and expected durations of effect for
andexanet alfa and ciraparantag, which are likely to vary depending on the individual oral anticoagulants.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Oral anticoagulants are widely used to reduce the risk of thrombo-
embolic events in patients with nonvalvular atrial ﬁbrillation.
Historically, the vitamin K antagonist, warfarin, was the oral anticoagu-
lant of choice, generating decades of experience and corresponding
data [1]. More recently, the direct oral anticoagulants (DOACs) have
gained widespread acceptance in the management of patients withngelheim Pharmaceuticals, Inc
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. This is an open access article undernonvalvular atrial ﬁbrillation and venous thromboembolism due in
part to their favorable safety, efﬁcacy, and ease of use when compared
with warfarin [2,3].
As expected with antithrombotic drugs, bleeding is the most com-
mon adverse event associated with the use of DOACs, whether precipi-
tated by the DOAC directly, by factors such as acute trauma or invasive
procedures, or by underlying comorbidities. Although bleeding-related
outcomes in clinical trials of DOACs in patients with atrial ﬁbrillation
have been favorable [4-7], the lack of a reversal agent often has been
considered as a disadvantage for DOACs [3,8]. This has prompted the de-
velopment of the speciﬁc reversal agents (reviewed in articles by Reilly
et al, Pollack, and Milling and Kaatz in this special issue) [9-11].
Idarucizumab (Boehringer Ingelheim International GmbH, Ingelheim,
Germany) is a humanized monoclonal antibody fragment that speciﬁ-
cally binds to dabigatran and is approved by the U.S. Food and Drug Ad-
ministration and the EuropeanMedicines Agency for use in dabigatran-
treated patients who require reversal of the anticoagulant effects of
dabigatran (ie, if there is life-threatening or uncontrolled bleeding, or
for emergency surgery/urgent procedures) [12]. There are a further 2
speciﬁc reversal agents in development: andexanet alfa (r-Antidote,
Portola Pharmaceuticals, Inc, South San Francisco, Calif), a factor Xa
decoy that binds to direct and indirect factor Xa inhibitors; andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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agent for both direct and indirect factor Xa inhibitors, as well as factor
IIa inhibitors [13,14].
The objective of this review is to provide practical guidance that can
be used when incorporating these DOAC—speciﬁc reversal agents into
existing guidelines and protocols for the management of serious bleed-
ing events or in patients undergoing urgent surgery while receiving
DOACs. The review also discusses how the individual reversal agents
may be used, as well as any unresolved issues that might be addressed
by ongoing and future trials.
1. Current guidelines and strategies for DOAC reversal
The European Heart Rhythm Association (EHRA) has provided guid-
ance for cliniciansmanaging bleeding events (Table 1) and surgical pro-
cedures in DOAC-treated patients with nonvalvular atrial ﬁbrillation, as
have other authors [15-18]. Likewise, the Neurocritical Care Society and
Society of Critical Care Medicine have devised guidelines for DOAC re-
versal in patients with intracranial hemorrhage [19].
1.1. Bleeding events and hemostasis
As a consequence of the short half-life and predictable pharmacoki-
netics of the DOACs, most bleeding events can be resolved simply by
waiting long enough (12-24 hours) for the DOAC plasma levels to de-
cline to subtherapeutic concentrationswhile providing supportivemea-
sures to the patient [15,20]. Key parameters thatwill guide the selection
of this “wait and support” approach are the timing of the last dose and
qualitative estimates from routine laboratory coagulation assays to es-
tablish the general range of the DOAC-induced anticoagulation effect.
In addition, factors inﬂuencing plasma concentrations should be taken
into consideration, such as drug—drug interactions and the patient’s
renal function. In patients receiving dabigatran, the time to drug elimi-
nation is strongly inﬂuenced by renal function. Dialysis may be consid-
ered to increase dabigatran clearance, although there is limited clinical
experience to support the use of dialysis in this setting [15,21].Table 1
European Heart Rhythm Association guidelines for practical measures to help control bleeding
Direct thrombin inhibitors (dabigatran)
Non-life-threatening
bleeding
Inquire last intake and dosing regimen
Estimate normalization of hemostasis:
Normal renal function: 12-24 h
CrCl 50-80 mL/min: 24-36 h
CrCl 30-50 mL/min: 36-48 h
CrCl b30 mL/min: ≥48 h
Maintain diuresis
Local hemostatic measures:
Fluid replacement (colloids if needed)
RBC substitution if necessary
Platelet substitution (in case of thrombocytopenia ≤60 x 109/L
thrombopathy)
Fresh-frozen plasma as plasma expander (not as reversal agen
Tranexamic acid can be considered as an adjuvant.
Consider dialysis (preliminary evidence: ~65% of dabigatran can be
removed after 4 h).
Charcoal hemoperfusion can be considered (based on preclinical da
Life-threatening
bleeding
All of the above
Idarucizumab 5 g IV
PCC 50 U/kg (with additional 25 U/kg if clinically needed) (but no
data)
Activated PCC (50 U/kg; max 200 U/kg/d), no strong data about ad
beneﬁt over PCC. Can be considered before PCC if available.
Activated FVII (rFVIIa; 90 μg/kg), no data about additional beneﬁt a
expensive (only animal evidence)
CrCl = creatinine clearance; FVII = factor VII; IV = intravenously; PCC = prothrombin compl
Adapted from Heidbuchel et al. [15]Patientswith life-threatening or uncontrolled bleeding, however, re-
quire more immediate reversal of the anticoagulant effects of DOACs.
Prothrombin complex concentrates and activated prothrombin com-
plex concentrates have been used for reversal of DOAC anticoagulation,
although their efﬁcacy has not been ﬁrmly established in prospective,
randomized trials [15,22] (see review by Eikelboom and Merli [23] in
this special issue). The potential anticoagulant reversal beneﬁts of
prothrombin complex concentrates and activated prothrombin com-
plex concentrates also need to be balanced against their potential
prothrombotic effects [15,24,25]. Both the updated EHRA practical
guide and the Neurocritical Care Society/Society of Critical Care Medi-
cine intracranial hemorrhage guidelines recommend administering
the recently approved reversal agent, idarucizumab, in patients receiv-
ing dabigatran [15,19]. A proposed algorithm for deciding if and when
to treatwith idarucizumab is provided in Figure. In the absence of a cur-
rently approved speciﬁc reversal agent for factor Xa inhibitors, these
guidelines recommend prothrombin complex concentrates or activated
prothrombin complex concentrates in patients receiving apixaban,
edoxaban, or rivaroxaban.1.2. Patients undergoing planned or urgent surgery
The EHRA practical guide also contains guidance on when to stop
DOAC therapy in patients undergoing a planned surgical procedure
that carries a bleeding risk. The timing of the withdrawal of the DOAC
is dependent on the particular agent, patient factors (eg, kidney func-
tion, age, history of bleeding, and concomitant medication), and the de-
gree of bleeding risk associated with individual procedures. Dabigatran
therapy should be stopped at least 24 to 48 hours ahead of low-risk pro-
cedures, depending on renal function, and at least 48 to 96 hours ahead
of high-risk procedures. The factor Xa inhibitors should be stopped at
least 24 to 36hours before low-risk procedures and at least 48 hours be-
fore high-risk procedures [12]. Common coagulation tests (eg, activated
partial thromboplastin time for dabigatran)may be helpful in providing
a qualitative evaluation of the waning anticoagulant effects, as may
speciﬁc coagulation tests (diluted thrombin time for dabigatran orin patients who are anticoagulated with a DOAC
Factor Xa inhibitors (apixaban, edoxaban, and rivaroxaban)
Inquire last intake and dosing regimen
Normalization of hemostasis: 12-24 h
or
t)
Local hemostatic measures:
Fluid replacement (colloids if needed)
RBC substitution if necessary
Platelet substitution (in case of thrombocytopenia ≤60 x 109/L or
thrombopathy)
Fresh-frozen plasma as plasma expander (not as reversal agent)
Tranexamic acid can be considered as an adjuvant.
Desmopressin can be considered in special cases (coagulopathy or
thrombopathy).
ta).
clinical
ditional
nd
All of the above
PCC 50 U/kg (with additional 25 U/kg if clinically needed) (healthy
volunteer data)
Activated PCC (50 U/kg; max 200 U/kg/d), no strong data about additional
beneﬁt over PCC. Can be considered before PCC if available.
Activated FVII (rFVIIa; 90 μg/kg), no data about additional beneﬁt and
expensive (only animal evidence)
ex concentrate; RBC = red blood cells; rFVIIa = recombinant factor VIIa
Figure. Suggested algorithm for themanagement of dabigatran-treated patients who experience a bleeding episode or who require urgent surgery/invasive procedures. *Administer two
50-mL vials of idarucizumab (each containing 2.5 g) intravenously. In rare caseswhen dabigatran-related anticoagulation persists after a course of idarucizumab, and bleeding continues in
the patient, a second 5 g dose of idarucizumab may be considered. aPTT = activated partial thromboplastin time; dTT = diluted thrombin time; TT = thrombin time. Reproduced with
permission from: Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI. Idarucizumab: the antidote for reversal of dabigatran. Circulation. 2015;132:2412-2422 [26].
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yet approved in the United States [15].
These stopping times may not always be feasible for more urgent
procedures, and in these cases, reversal of anticoagulation is required.
As is the case in patients with life-threatening bleeding, prospective
data on the use of prothrombin complex concentrates in the preopera-
tive setting are lacking [15]. Patients receiving dabigatran who require
emergency surgery or urgent procedures may receive idarucizumab
(administered as 2 consecutive intravenous infusions of 2.5 g in 50 mL
apiece) for the reversal of dabigatran (Figure) [12]. A published interim
analysis of the phase 3, cohort study REVERSal Effects of Idarucizumab
in Patients on Active Dabigatran (RE-VERSE AD) included 39 patients
receiving dabigatran who required a surgery or procedure that could
not be delayed for at least 8 hours and required normal hemostasis
[27,28]. In these patients, idarucizumab reversed the anticoagulant ef-
fects of dabigatran (as assessed by diluted thrombin time or ecarin
clotting time) in 93% and 88% of patients, respectively. Of note,
idarucizumab obviated the need for surgery in 1 patient, and 2 patients
were too unstable for surgery. In the 36 patients who subsequently had
a procedure, 33 were considered to have normal intraoperative hemo-
stasis by the investigator [27].
2. Key considerations for speciﬁc reversal agents
With the increasing availability of the speciﬁc reversal inhibitors, cli-
nicians will be required to incorporate these agents into their institu-
tional guidelines/protocols for the urgent reversal of DOACs. This will
raise a number of considerations, which are discussed in the followingsections. Because conditions can vary between institutions, each organi-
zationmay need to adapt existing guidelines to their particular situation
as they consider the key factors that inﬂuence patient outcomes. An ex-
ample of a template local guidance document can be found in Table 2,
which is provided as a starting point for the development of more indi-
vidualized local protocols.
2.1. Appropriate patient selection
As discussed earlier, the use of speciﬁc reversal agents should be
reserved for life-threatening bleeding or in patients in whom an urgent
invasive procedure is required. The approved uses for these agents
are likely to differ on the basis of the patient populations studied in
phase 3 trials. The idarucizumab phase 3 trial (RE-VERSE AD) included
adult patients with overt, uncontrollable, or life-threatening bleeding
(group A) or who required surgery or other invasive procedures
that could not be delayed for at least 8 hours (group B) [27,28]. Patients
were selected on the basis of clinical judgment that immediate reversal
was required and included those with acute trauma, as well as
those who were expected to die within 3 days or require surgery within
24 hours [27]. The approved indication for idarucizumab reﬂects this
trial population [12].
In contrast, the ongoing phase 3 andexanet alfa trial (Andexanet Alfa a
Novel Antidote to the Anticoagulant Effects of FXa Inhibitors [ANNEXA]-4;
NCT02329327) includes patients with an acute major bleeding episode re-
quiring urgent reversal of apixaban, rivaroxaban, edoxaban, or enoxaparin
(administered in the past 18 hours) [29]. Patients expected to undergo sur-
gery (excludingminimally invasive procedures) in b12 hours are excluded,
Table 2
Considerations regarding potential use of idarucizumab: prototypical table to guide decision-making
Indications Life-threatening or uncontrolled bleeding Emergency surgery or invasive
procedures
Mild to moderate bleeding
Criteria Life-threatening bleeding leading to hemodynamic
compromise or threatening a vital organ (eg, CNS or
spinal cord, intraocular, intrapulmonary,
retroperitoneal, or intramuscular with compartment
syndrome)
Unresponsive to conventional measures
Potentially leading to disability
Emergency surgery or urgent
procedures that cannot be delayed for
at least 8 h and that require
immediate hemostasis
Non—life-threatening bleeding that does
not involve a vital organ or in patients in
whom surgery or invasive procedures can
be delayed⁎
⁎Idarucizumab is NOT indicated for cases of
mild or moderate bleeding.
Baseline laboratory tests to
assess anticoagulation
Need to order aPTT, ECT, or dTT in all patients when possible (depending on local availability of individual assays):
Coagulation assay times that may indicate signiﬁcant elevation of coagulation parameters (results need to be considered in light of local assay standards):
aPTT (median baseline PTT ~50 sec)† [21]
ECT (median baseline ECT ~75 sec)† [27]
dTT (median baseline dTT ~45 sec)† [27]
Dabigatran ingestion
conﬁrmed?
Known timing/ingestion of dabigatran (prescribed anticoagulant, standard dosage, known last dose?)
Potential dabigatran overdose (accidental, deliberate?)
Expected minimum timing for elimination of
clinically relevant dabigatran concentrations:
CrCl ≥50 mL/min: ≥24 h
CrCl b50 mL/min: ≥48 h
Idarucizumab Consider administering idarucizumab immediately Idarucizumab is not recommended for
cases of mild to moderate bleeding.
Dosing Intravenous administration of idarucizumab; 5 g total dose administered as 2 consecutive
infusions or bolus injections of 2.5 g/50 mL each
Not applicable
Monitoring Signs and symptoms of bleeding or thrombotic events
Repeat aPTT, ECT, or dTT at 4 h and at 12-24 h postadministration (as per local protocols)
Local resources Names and contact information of local experts, ofﬁces, and laboratories that are available to
guide patient selection and treatment choices
aPTT= activated partial thromboplastin time; CNS= central nervous system; CrCl= creatinine clearance; dTT=dilute thrombin time; ECT= ecarin clotting time; PTT=partial throm-
boplastin time
† Rounded median baseline values for each assay for patients taking dabigatran, as per listed citation. Values are provided for general guidance only; need to consider performance of
each assay under local or central laboratory conditions.
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tients also is based on a set of predeﬁned criteria: acute bleeding that is po-
tentially life-threatening, in a critical area or organ, or associated or
expected to be associated with decreases in hemoglobin levels of ≥2 g/dL
or current or expected hemoglobin levels of ≤8 g/dL. Thus, these criteria
are similar to the current International Society for Thrombosis and
Haemostasis guidelines for nonsurgical patients, although patients who
have received blood products (including whole blood and prothrombin
complex concentrates) in the past 7 days are excluded [30]. When consid-
ering the magnitude of bleeding that may require urgent reversal, the var-
iability in major bleeding deﬁnitions used in DOAC trials should be taken
into account, as should the variability in deﬁnitions of effective
periprocedural hemostasis, which are used to determine the effectiveness
of management strategies [4-7,31].
The differing mode of actions or drug targets of the individual agents
(Table 3) will need to be taken into consideration when selecting the ap-
propriate agent. Idarucizumab is speciﬁc to and only effective against
dabigatran [27,28,38], whereas andexanet alfa has been developed to tar-
get the currently approved factor Xa inhibitors [8,13] (andnot dabigatran),
and ciraparantag has been designed as a “universal” inhibitor for DOACs
and heparins [33-35,37]. Therefore, the decision regarding which agent
to usewill dependonwhich particular DOAC is prescribed. Patients receiv-
ing speciﬁc reversal agents will need to receive additional supportive care
to control bleeding because the reversal agents have been designed to re-
verse the anticoagulant effect of DOACs rather than to control bleeding.
2.2. Dosing and administration
The 3 speciﬁc reversal agents are all administered intravenously,
with andexanet alfa requiring an infusion pump. The recommendeddose of idarucizumab is 5 g, which is supplied in 2 separate vials
(2.5 g/50 mL idarucizumab per vial) that are ready for administration
by sequential bolus injections or continuous intravenous infusion [12].
The vials need to be stored at a temperature range of 36°F to 46°F, with-
out freezing. Likewise, andexanet alfa is a recombinant protein product
that may need to be refrigerated and is expected to be administered at
different doses according to the particular factor Xa inhibitor in ques-
tion. In light of these recommendations, each institutionwill need to de-
ﬁne its “best option” storage location on the basis of internal inventory
control procedures and the relative ease-of-access in emergency situa-
tions. Ciraparantag is stable at room temperature, and thus, has the po-
tential for out-of-hospital use.
In the RE-VERSE AD trial, idarucizumab demonstrated immediate
neutralization of dabigatran’s anticoagulant activity [27]. However, in-
creases in unbounddabigatran concentration,whichwere accompanied
by prolonged diluted thrombin time and ecarin clotting time values,
occurred in some patients at 12 or 24 hours. This may be attributed
to the redistribution of dabigatran from the tissues back into the
plasma [27] and highlights the need for an approved and accessible
assay for dabigatran, such as diluted thrombin time or activated partial
thromboplastin time. Administration of an additional 5-g dose of
idarucizumab may be considered in patients who have reappearance
of clinically relevant bleeding together with an elevated coagulation pa-
rameter after administration of idarucizumab [12,41]. Likewise,
readministration of idarucizumab may be considered in patients who
require a second emergency procedure and have elevated coagulation
parameters. However, the safety and effectiveness of repeat treatment
with idarucizumab have yet to be established.
Findings from phase 2 trials suggest that the dose of andexanet alfa
will vary depending on the anticoagulant agent (see review by Milling
Table 3
Reversal agent characteristics
Speciﬁc reversal
agent
Molecular entity Mechanism of action Target(s) Route of administration Time to/duration of
response
Clinical trial patient
populations
Andexanet alfa Recombinant
protein derived from
human FXa [8,13]
Designed to competitively
bind FXa inhibitors with
high afﬁnity, but lacks
catalytic activity of native
FXa [8,13]
Direct FXa inhibitors
LMWH
Fondaparinux [8,13]
By IV bolus or direct
infusion [8,32]
Effect noted by 5 min, peak
effect will last ~2 h after
bolus injection or for 1-2 h
after 2-h infusion [8,32]
Healthy older volunteers [32]
Ciraparantag Engineered small
molecule [33-35]
Binds heparins, oral FXa and
FIIa inhibitors via extensive
hydrogen bonds [33-35]
Direct FXa inhibitors
DTI
LMWH
Heparin
Fondaparinux [33-35]
By single IV bolus
[33,36]
Effect begins within 30 min,
lasts up to 24 h [33-35]
Healthy volunteers [36,37]
Idarucizumab Fully humanized
monoclonal
antibody fragment
(Fab) [38]
High afﬁnity binding to
dabigatran [38]
Dabigatran [38] Via short IV infusion or
bolus injection [12]
Immediate onset, effect
will last up to 24 h [27,39]
Healthy volunteers [39,40]
Patients with serious bleeding
or in need of emergent
invasive procedures
DTI = direct thrombin inhibitor; FIIa = factor IIa; FXa = factor Xa; IV = intravenous; LMWH= low-molecular-weight heparin
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ANNEXA-A and ANNEXA-R trials resulted in reversal of the anticoagulant
activity of apixaban or rivaroxaban in older healthy participants within
minutes after administration and for the duration of the infusion [32].
However, the appropriate dose of andexanet alfa for apixaban or
rivaroxaban in patients with bleeding complications has yet to be deﬁned
andmay vary depending on the time since the last anticoagulant dose, the
total body load of the anticoagulant agent, and the underlying renal func-
tion. Guidance will be required regarding the optimal duration of the in-
fusion, especially because a readily available laboratory test to quantify
levels of factor Xa anticoagulation is currently lacking in the United
States. In addition, andexanet alfa doses and durations of therapy to
reverse the effects of low-molecular-weight heparins or fondaparinux
will need to be deﬁned, as will the appropriate doses of ciraparantag to
reverse the effects of the different anticoagulants in clinical use.
2.3. Coadministration with nonspeciﬁc hemostatic agents
As speciﬁc reversal agents continue to be approved for the reversal
of DOACs (factor II or factor Xa inhibitors), the role, if any, that the
currently available coagulation factors or concentrates play in the
management of pathologic bleeding events can be expected to evolve
[15,20,42]. However, there is limited clinical experience with the use
of coagulation concentrates and DOAC-speciﬁc reversal agents. Patients
with bleeding in the RE-VERSE AD trial were permitted to receive sup-
portive care, including prothrombin complex concentrates and other
blood products, during the trial [28]. Consequently, of theﬁrst 90 patients,
4 received activated prothrombin complex concentrates and 23 received
fresh-frozen plasma [27]. However, outcomes data for these patients have
not been reported. Furthermore, blood products, including prothrombin
complex concentrates, are not permitted in the ongoing major bleeding
andexanet alfa ANNEXA-4 trial within 7 days of screening [29].
2.4. Re-initiation of anticoagulant therapy
Clinicians also will need to decide when anticoagulation should be
reestablished after use of a speciﬁc reversal agent. This will be dependent
on the patient’ s individual risk of bleeding versus thromboembolism, but
will also need to take into account the reversal agent used. In healthy vol-
unteers, dabigatran anticoagulation could be reestablished within 24
hours of idarucizumab use [41]. In the RE-VERSE AD trial, most patients
re-initiated anticoagulant therapy after reversal, with the restart time
varying: a median time of 4.1 days in patients with life-threatening
bleeding versus 1.4 days in patients requiring urgent surgery [43].
Although the half-lives of dabigatran and idarucizumab are prolonged
in patients with renal impairment, the adjustment of timing of re-
initiation of dabigatran is not necessary [12,21]. Data are required toidentify when anticoagulation may be re-established after andexanet
alfa or ciraparantag use, particularly if patients require an emergent pro-
cedure with extracorporeal life support and immediate heparinization.
2.5. Safety
No safety concerns for idarucizumab were highlighted in the RE-
VERSE AD trial; the 18 deaths that were reported were due to the
index event or underlying condition, and the 5 thrombotic events (in-
cluding 1 occurring within 72 hours of idarucizumab administration)
were in patients who had not re-initiated anticoagulant therapy [27].
This is in line with preclinical and phase 1 trials in which idarucizumab
showed no prothrombotic effects (see the review by Reilly et al in this
special issue) [9]. In addition, it should be noted that there is a risk of se-
rious adverse events with idarucizumab use in patients with hereditary
fructose intolerance resulting from the sorbitol excipient [12].
The safety of andexanet alfa and ciraparantag has yet to be established
in patients with bleeding complications. Although andexanet alfa has
demonstrated no procoagulant activity in ex vivo clotting assays [13],
transient increases in the levels of D-dimer and prothrombin 1 and 2
were reported in the ANNEXA-A and ANNEXA-R trials [32]. However,
this did not result in increases in thrombin generation or thrombotic
events in these healthy volunteers. Even so, safety data from patients
withmajor bleedingwill be required to exclude apotential prothrombotic
effect with andexanet alfa use.
As with all proteins, there is a potential for immunogenicity with
both idarucizumab and andexanet alfa. However, preliminary data
from trials in healthy volunteers suggest that this may not be a concern
for idarucizumab because it has not been associated with the formation
of new persistent antibodies, and there were no adverse events sugges-
tive of immunogenic reactions [39]. Likewise, in the ANNEXA-A and
ANNEXA-R trials, antibodies to factor X or factor Xa, as well as neutral-
izing antibodies against andexanet alfa, were not detected [32]. Howev-
er, further research will be required to assess the immunogenicity of
idarucizumab or andexanet alfa in treated patients.
3. Conclusions
Considerations of speciﬁc anticoagulation reversal agents are ex-
pected to include questions regarding the appropriate clinical setting
for these agents. It is not anticipated that these agents will be used to
manage mild or moderate bleeding events, which are usually well con-
trolled by general supportive measures. Most likely, the role of speciﬁc
reversal agents will be to help treat serious bleeding events in DOAC-
treated patients. At the present time, the approved indications for
idarucizumab are for cases of life-threatening or uncontrolled bleeding,
orwhen patients require emergency surgery or urgent procedures, each
51M.V. Huisman, J. Fanikos / American Journal of Emergency Medicine 34 (2016) 46–51associated with a high risk of bleeding [12]. Ongoing clinical research
should address unresolved issues, such as the optimal dose and duration
for andexanet alfa and ciraparantag in patients with bleeding complica-
tions, as well as DOAC re-initiation strategies after treatmentwith these
reversal agents, particularly in patients in whom emergent reversal of
anticoagulation is required.
As clinical experience continues to evolve, the potential role of pro-
thrombin complex concentrates and other nonspeciﬁc agents as sup-
portive therapy in combination with speciﬁc reversal agents will be
better understood [20]. In addition, the identiﬁcation of potential “go-
to” local experts (eg, hematologists, cardiologists, or pharmacists) at
each institution, who should be consulted in cases of severe and uncon-
trolled bleeding,will be expected to improve patient care andoutcomes.
Finally, the relevant clinical societies may be asked to support the
widespread availability of these speciﬁc reversal agents in all major
and regional hospitals so that critical cases may be treated as urgently
as possible. For the smaller, regional hospitals and rural healthcare facil-
ities, ultimate decisions to maintain stocks of these agents may depend
on local conditions. They will have to assess the cost—beneﬁt of relying
on rapid transportation options or onsite availability of each agent as
they become available.
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